

FOI 3146

6th June 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Response:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	17
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	1
1.4 Fulvestrant (fulvestrant or Faslodex)	**Fee limit
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	32
1.7 Ribociclib (Kisqali)	15
1.8 Capivasertib (Truqap)	2
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	2

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

How many patients received the following medicines for early breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Response:

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	**Fee limit
2.2 Ribociclib (Kisqali)	**Fee limit
2.3 Olaparib (Lynparza)	1

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

How many patients received the following medicines with curative treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Response:

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	**Fee limit
3.2 Ribociclib (Kisqali)	**Fee limit

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.



How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Response:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	**Fee limit
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	**Fee limit
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	**Fee limit

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?

Response:

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	2
5.2 Locally advanced or metastatic breast cancer	1

How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0

6.2 Pertuzumab with Trastuzumab (Phesgo)	32
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	25
6.4 Trastuzumab Deruxtecan (EnHertu)	5
6.5 Trastuzumab Emtansine (Kadcyla)	7
6.6 Tucatinib (Tukysa)	0
6.7 Neratinib (Nerlynx)	0

How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	25
7.2 Trastuzumab Deruxtecan (EnHertu)	5

How many patients received the following products with curative treatment intent in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Response:

Treatment intent	Number patients treated
8.1 Pertuzumab (Perjeta)	**Fee limit
8.2 Pertuzumab with Trastuzumab (Phesgo)	**Fee limit
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	**Fee limit
8.4 Trastuzumab Emtansine (Kadcyla)	**Fee limit

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Response:

Treatment intent	Number patients treated
9.1 Pertuzumab (Perjeta)	**Fee limit
9.2 Pertuzumab with Trastuzumab (Phesgo)	**Fee limit
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	**Fee limit
9.4 Trastuzumab Emtansine (Kadcyla)	**Fee limit

** This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Response:

Treatment intent	Number patients treated
10.1 HER2+ ve Breast Cancer	5
10.2 HER2- low Breast Cancer	0